Lexicon Pharmaceuticals, Inc.

Entry into a Material Definitive Agreement Underwriting Agreement On January 29, 2026, Lexicon Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwrit

by reference. A total of 23,100,000 shares of Common Stock are issuable upon conversion of the maximum issuable number of shares Preferred Stock pursuant to the

Material Modification to Rights of Security Holders To the extent required, the information regarding the Certificate of Designations (as defined below) set for

of this Current Report on Form 8-K is incorporated herein by reference. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Cert

shall not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely to satisfy the requirem

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Underwriting Agreement, dated as of January 29, 2026, by and among Lexicon Pharm